Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNAGlobeNewsWire · Sep 28, 2026
Reviewing Codexis (NASDAQ:CDXS) & Revvity (NYSE:RVTY)Defense World · Sep 24, 2026
Analyzing Codexis (NASDAQ:CDXS) and Mettler-Toledo International (NYSE:MTD)Defense World · Sep 24, 2026
BlackRock Inc. Makes New Investment in Codexis, Inc. $CDXSDefense World · Sep 4, 2026
Codexis to Participate in Cantor Global Healthcare Conference 2026GlobeNewsWire · Aug 27, 2026
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research · Aug 14, 2026Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.14 | -$0.13 | Beat |
| May 7, 2026 | -$0.11 | -$0.10 | Beat |
| Mar 11, 2026 | $0.01 | $0.11 | Beat |
| Nov 6, 2025 | -$0.15 | -$0.22 | Miss |
| Aug 13, 2025 | -$0.17 | -$0.16 | Beat |
| May 14, 2025 | -$0.20 | -$0.25 | Miss |